Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmos Health has the GF Score of 27, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Cosmos Health
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Cosmos Health (FRA:V67A) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Cosmos Health GF Score Related Terms
FRA:V67A vs HKPD, SNYR, YI: GF Score Comparison
For the Medical Distribution subindustry, Cosmos Health's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmos Health GF Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cosmos Health's GF Score distribution charts can be found below:
* The bar in red indicates where Cosmos Health's GF Score falls into.
Cosmos Health (FRA:V67A) has a GF Score of 27 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cosmos Health and its competitors. This is 31% below median its historical median of 39.00. Over the past decade, Cosmos Health's GF Score has ranged from 17.00 to 68.00.
Is Cosmos Health's GF Score too high?
Cosmos Health's current GF Score of 27 is 31% below median its 10-year median of 39.00. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 68.00. Overall, Cosmos Health has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's GF Score compare to HKPD and SNYR?
Cosmos Health's GF Score of 27 can be compared against companies in the Medical Distribution industry. Historically, Cosmos Health's own GF Score has ranged from 17.00 to 68.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Distribution company?
A good GF Score depends on the Medical Distribution industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cosmos Health and its competitors. Cosmos Health's current GF Score is 27, which is 31% below median its own 10-year median of 39.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (FRA:V67A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.27 — trading 14.6% below its estimated fair value. The current GF Score is 27, which is 31% below median its 10-year median of 39.00. Cosmos Health's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Cosmos Health (FRA:V67A), the current GF Score is 27 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmos Health (FRA:V67A) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued.
The current stock price of €0.27 is trading 14.6% below its estimated GF Value™ of €0.32.
GuruFocus considers Cosmos Health to be Modestly Undervalued.
Key valuation signals for FRA:V67A:
GF Score: 27 (31% below median its 10-year median of 39.00)
GF Value™: €0.32 vs. price of €0.27 (14.6% below fair value)
No single metric tells the full story. See the FRA:V67A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
27GF Score
Get the complete analysis for FRA:V67A
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V67A has been successfully added to your 
